Menu

Investors

2025 Full year and fourth quarter announcement

We announced our full year and fourth quarter 2025 results on Wednesday 4 February.

Q4 2025 resultsAnnual Report 2025
FY 2025 Luke Miels
Close video

We’re confident in our future

With our strong momentum and improving outlook for sustained growth through the decade, we're confident in our ability to deliver human health impact at scale, worldwide.

Why invest in GSK?

Speeches and presentations

David Redfern

UBS European Healthcare Conference

04 March 2026

David Redfern, President Corporate Development, attended the UBS European Healthcare Conference in London on Wednesday, 4 March 2026.

GSK and 35 Pharma logo

GSK enters agreement to acquire 35Pharma Inc.

25 February 2026

Sell-side analysts calls with Nina Mojas, President, Global Product Strategy and Kaivan Khavandi, SVP, R&D Head, Respiratory, Immunology & Inflammation.

GSK and RAPT logo

GSK enters agreement to acquire RAPT Therapeutics

20 January 2026

Sell-side analysts calls with Luke Miels, Chief Executive Officer, Tony Wood, Chief Scientific Officer and Nina Mojas, President, Global Product Strategy.

Tony Wood

J.P. Morgan 2026 Healthcare Conference, San Francisco

13 January 2026

Tony Wood, Chief Scientific Officer, participated in a fireside chat during the J.P. Morgan 2026 Healthcare Conference in San Francisco on Tuesday, 13 January 2026.

Deborah Waterhouse

Citi 2025 Global Healthcare Conference, Miami

04 December 2025

Deborah Waterhouse, Chief Executive Officer of ViiV Healthcare, and Dr. Kimberly Smith, Head of R&D at ViiV Healthcare, participated at the Citi 2025 Global Healthcare Conference in Miami on Thursday, 4 December 2025.

Shareholder information

Shareholder information

GSK dividend

GSK laboratory photo

Dividend calculators (GBp/USD)

Calculate an estimate of your dividend payment

GSK lab equipment photo

Dividend calendar

Details of our dividend timetable by quarter

GSK share price

Share price tool

Detailed information on GSK's share price, including an interactive chart

Go to share price tool

Behind the Science

Read our latest articles

Mapping disease at the cellular level: A single-cell revolution in drug discovery

Why adults aged 50 years and older with certain long-term health conditions need to make their move to help protect against this common respiratory virus

'The ever-present threat of contracting a UTI means my daily routine is ruled by measures to reduce my risk'

'We’re innovating to help keep COPD patients out of hospital and exacerbation-free'

'Prevention is the best medicine to stop disease before it starts'

‘I was the sickest anyone could ever be’: Why young people are at risk of meningitis and what needs to change to reduce it

‘Digital biological twins and organoids might sound like sci-fi, but they’re real – and we’re using them to fight cancer’

‘I feel hopeless and frustrated’: Why patients living with incurable blood cancers need more treatment options

‘Finding the right treatment for my asthma and nasal polyps has transformed my life. I hope my experience can help others achieve the same’

‘How do we improve trust in prevention? The answer lies closer to home than you might think’

Behind the Science magazine
two scientists talking

Get in touch with our investor team

Investor contact details

You might also like

Pipeline

Our pipeline is focused on unlocking the science of the immune system and advanced technologies to develop innovative medicines and vaccines

Our leading scientists

Meet the world-leading scientists who are uniting science, technology and talent to get ahead of disease together.

Governance

At GSK we are committed to operating at the highest standards of corporate governance

Continue to Media